Dengue — Sri Lanka
Nearly 50 percent of the world’s population is considered at risk of infection with dengue virus (DENV), a mosquito-borne RNA virus that can potentially cause lethal disease. The efficacy of currently approved vaccines is poor in people who have not previously encountered DENV. Afroz et al. found that pretreatment of mice with the amino acid starvation mimetic halofuginone (HF) increased the adaptive immune response to a DENV vaccine. Known to activate the nutrient-sensing kinase GCN2, HF
…
